-
C.
Goodman,
C.
Speers
(2020)
The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions.
International journal of radiation oncology, biology, physics
-
T.
Fehm,
O.
Hoffmann,
B.
Aktas,
S.
Becker,
E.
Solomayer,
D.
Wallwiener,
R.
Kimmig,
S.
Kasimir-Bauer
(2009)
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
Breast Cancer Research : BCR, 11
-
A.
Bardia,
I.
Mayer,
L.
Vahdat,
S.
Tolaney,
S.
Isakoff,
J.
Diamond,
J.
O’Shaughnessy,
R.
Moroose,
A.
Santin,
V.
Abramson,
N.
Shah,
H.
Rugo,
D.
Goldenberg,
A.
Sweidan,
R.
Iannone,
Sarah
Washkowitz,
R.
Sharkey,
W.
Wegener,
K.
Kalinsky
(2019)
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
The New England Journal of Medicine, 380
-
F.
Bidard,
S.
Baffert,
D.
Hajage,
E.
Brain,
Sébastien
Armanet,
C.
Simondi,
L.
Mignot,
B.
Asselain,
P.
Tresca,
J.
Pierga
(2012)
Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial
Cancer Research, 72
-
M.
Colleoni,
M.
Bonetti,
A.
Coates,
M.
Castiglione‐Gertsch,
R.
Gelber,
K.
Price,
C.
Rudenstam,
J.
Lindtner,
J.
Collins,
B.
Thürlimann,
S.
Holmberg,
A.
Veronesi,
G.
Marini,
A.
Goldhirsch
(2000)
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 3
-
(
YuM
BardiaA
AcetoN
, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science
2014; 345: 216–220.25013076)
YuM
BardiaA
AcetoN
, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science
2014; 345: 216–220.25013076
YuM
BardiaA
AcetoN
, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science
2014; 345: 216–220.25013076,
YuM
BardiaA
AcetoN
, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science
2014; 345: 216–220.25013076
-
N.
Aceto,
A.
Bardia,
D.
Miyamoto,
M.
Donaldson,
Ben
Wittner,
J.
Spencer,
Min
Yu,
Adam
Pely,
Amanda
Engstrom,
Huili
Zhu,
Brian
Brannigan,
R.
Kapur,
Shannon
Stott,
T.
Shioda,
Sridhar
Ramaswamy,
D.
Ting,
Charles
Lin,
M.
Toner,
D.
Haber,
S.
Maheswaran
(2014)
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Cell, 158
-
(
SymmansWF
PeintingerF
HatzisC
, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol
2007; 25: 4414–4422.17785706)
SymmansWF
PeintingerF
HatzisC
, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol
2007; 25: 4414–4422.17785706
SymmansWF
PeintingerF
HatzisC
, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol
2007; 25: 4414–4422.17785706,
SymmansWF
PeintingerF
HatzisC
, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol
2007; 25: 4414–4422.17785706
-
(
RackBK
SchindlbeckC
AndergassenU
, et al. Use of CTCs in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: the SUCCESS trial. J Clin Oncol
2010; 28: abstract 1003.)
RackBK
SchindlbeckC
AndergassenU
, et al. Use of CTCs in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: the SUCCESS trial. J Clin Oncol
2010; 28: abstract 1003.
RackBK
SchindlbeckC
AndergassenU
, et al. Use of CTCs in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: the SUCCESS trial. J Clin Oncol
2010; 28: abstract 1003.,
RackBK
SchindlbeckC
AndergassenU
, et al. Use of CTCs in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: the SUCCESS trial. J Clin Oncol
2010; 28: abstract 1003.
-
(
LeeSK
KimGS
WuY
, et al. Nanowire substrate-based laser scanning cytometry for quantification of circulating tumor cells. Nano Lett
2012; 12: 2697–2704.22646476)
LeeSK
KimGS
WuY
, et al. Nanowire substrate-based laser scanning cytometry for quantification of circulating tumor cells. Nano Lett
2012; 12: 2697–2704.22646476
LeeSK
KimGS
WuY
, et al. Nanowire substrate-based laser scanning cytometry for quantification of circulating tumor cells. Nano Lett
2012; 12: 2697–2704.22646476,
LeeSK
KimGS
WuY
, et al. Nanowire substrate-based laser scanning cytometry for quantification of circulating tumor cells. Nano Lett
2012; 12: 2697–2704.22646476
-
J.
Baselga,
I.
Bradbury,
H.
Eidtmann,
S.
Cosimo,
E.
Azambuja,
C.
Aura,
H.
Gómez,
P.
Dinh,
K.
Fauria,
V.
Dooren,
G.
Aktan,
A.
Goldhirsch,
Tsai-Wang
Chang,
Z.
Horváth,
M.
Coccia-Portugal,
J.
Dômont,
L.
Tseng,
G.
Kunz,
J.
Sohn,
V.
Semiglazov,
G.
Lerzo,
M.
Pálácova,
V.
Probachai,
L.
Pusztai,
M.
Untch,
R.
Gelber,
M.
Piccart-Gebhart
(2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
The Lancet, 379
-
Min
Yu,
A.
Bardia,
N.
Aceto,
Francesca
Bersani,
M.
Madden,
M.
Donaldson,
R.
Desai,
Huili
Zhu,
Valentine
Comaills,
Zongli
Zheng,
Ben
Wittner,
P.
Stojanov,
E.
Brachtel,
D.
Sgroi,
R.
Kapur,
T.
Shioda,
D.
Ting,
Sridhar
Ramaswamy,
G.
Getz,
A.
Iafrate,
C.
Benes,
M.
Toner,
S.
Maheswaran,
D.
Haber,
D.
Haber
(2014)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Science, 345
-
F.
Bidard,
T.
Fehm,
M.
Ignatiadis,
J.
Smerage,
C.
Alix-Panabières,
W.
Janni,
C.
Messina,
C.
Paoletti,
V.
Müller,
D.
Hayes,
M.
Piccart,
J.
Pierga
(2012)
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
Cancer Metastasis Reviews, 32
-
(
BredemeierM
EdimirisP
TewesM
, et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget2016; 7: 41677–41690.27223437)
BredemeierM
EdimirisP
TewesM
, et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget2016; 7: 41677–41690.27223437
BredemeierM
EdimirisP
TewesM
, et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget2016; 7: 41677–41690.27223437,
BredemeierM
EdimirisP
TewesM
, et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget2016; 7: 41677–41690.27223437
-
M.
Serrano,
P.
Rovira,
I.
Martinez-Zubiaurre,
Miguel
Rodríguez,
M.
Fernández,
J.
Lorente
(2012)
Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy.
Experimental and therapeutic medicine, 4 1
-
T.
Molloy,
L.
Devriese,
H.
Helgason,
A.
Bosma,
M.
Hauptmann,
E.
Voest,
J.
Schellens,
J.
Schellens,
L.
Veer
(2011)
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
British Journal of Cancer, 104
-
(
RastogiP
AndersonSJ
BearHD
, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986)
RastogiP
AndersonSJ
BearHD
, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986
RastogiP
AndersonSJ
BearHD
, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986,
RastogiP
AndersonSJ
BearHD
, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol
2008; 26: 778–785.18258986
-
P.
Cortazar,
Lijun
Zhang,
M.
Untch,
K.
Mehta,
J.
Costantino,
N.
Wolmark,
H.
Bonnefoi,
D.
Cameron,
L.
Gianni,
P.
Valagussa,
S.
Swain,
Tatiana
Prowell,
S.
Loibl,
L.
Wickerham,
J.
Bogaerts,
J.
Baselga,
C.
Perou,
G.
Blumenthal,
J.
Blohmer,
E.
Mamounas,
J.
Bergh,
V.
Semiglazov,
R.
Justice,
H.
Eidtmann,
S.
Paik,
M.
Piccart,
R.
Sridhara,
P.
Fasching,
L.
Slaets,
Shenghui
Tang,
B.
Gerber,
C.
Geyer,
R.
Pazdur,
N.
Ditsch,
P.
Rastogi,
W.
Eiermann,
G.
Minckwitz
(2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
The Lancet, 384
-
G.
Minckwitz,
A.
Schneeweiss,
S.
Loibl,
C.
Salat,
C.
Denkert,
M.
Rezai,
J.
Blohmer,
C.
Jackisch,
S.
Paepke,
B.
Gerber,
D.
Zahm,
S.
Kümmel,
H.
Eidtmann,
P.
Klare,
J.
Huober,
S.
Costa,
H.
Tesch,
C.
Hanusch,
J.
Hilfrich,
F.
Khandan,
P.
Fasching,
B.
Sinn,
K.
Engels,
K.
Mehta,
V.
Nekljudova,
M.
Untch
(2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
The Lancet. Oncology, 15 7
-
(
SabatierR
PiergaJY
CuréH
, et al. Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer: ancillary analysis of the AVASTEM trial. Cancers (Basel)
2021; 13: 1–13.)
SabatierR
PiergaJY
CuréH
, et al. Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer: ancillary analysis of the AVASTEM trial. Cancers (Basel)
2021; 13: 1–13.
SabatierR
PiergaJY
CuréH
, et al. Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer: ancillary analysis of the AVASTEM trial. Cancers (Basel)
2021; 13: 1–13.,
SabatierR
PiergaJY
CuréH
, et al. Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer: ancillary analysis of the AVASTEM trial. Cancers (Basel)
2021; 13: 1–13.
-
W.
Symmans,
F.
Peintinger,
C.
Hatzis,
Radhika
Rajan,
H.
Kuerer,
V.
Valero,
L.
Assad,
A.
Poniecka,
B.
Hennessy,
Marjorie
Green,
A.
Buzdar,
S.
Singletary,
G.
Hortobagyi,
L.
Pusztai
(2007)
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 28
-
(
RackB
SchindlbeckCh
JückstockJ
, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst
2014; 106: 1–11.)
RackB
SchindlbeckCh
JückstockJ
, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst
2014; 106: 1–11.
RackB
SchindlbeckCh
JückstockJ
, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst
2014; 106: 1–11.,
RackB
SchindlbeckCh
JückstockJ
, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst
2014; 106: 1–11.
-
(
SparanoJ
O’NeillA
AlpaughK
, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol
2018; 4: 1700–1706.30054636)
SparanoJ
O’NeillA
AlpaughK
, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol
2018; 4: 1700–1706.30054636
SparanoJ
O’NeillA
AlpaughK
, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol
2018; 4: 1700–1706.30054636,
SparanoJ
O’NeillA
AlpaughK
, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol
2018; 4: 1700–1706.30054636
-
L.
Gianni,
T.
Pieńkowski,
Y.
Im,
L.
Roman,
L.
Tseng,
Mei-Ching
Liu,
A.
Lluch,
E.
Starosławska,
J.
Haba-Rodríguez,
S.
Im,
J.
Pedrini,
B.
Poirier,
P.
Morandi,
V.
Semiglazov,
V.
Srimuninnimit,
G.
Bianchi,
T.
Szado,
J.
Ratnayake,
G.
Ross,
P.
Valagussa
(2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
The Lancet. Oncology, 13 1
-
M.
Mego,
A.
Giordano,
U.
Giorgi,
H.
Masuda,
L.
Hsu,
M.
Giuliano,
T.
Fouad,
S.
Dawood,
N.
Ueno,
V.
Valero,
E.
Andreopoulou,
R.
Alvarez,
W.
Woodward,
G.
Hortobagyi,
M.
Cristofanilli,
J.
Reuben
(2015)
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Breast Cancer Research : BCR, 17
-
(
BearHD
AndersonS
SmithRE
, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J CIin Oncol
2006; 24: 2019–2027.)
BearHD
AndersonS
SmithRE
, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J CIin Oncol
2006; 24: 2019–2027.
BearHD
AndersonS
SmithRE
, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J CIin Oncol
2006; 24: 2019–2027.,
BearHD
AndersonS
SmithRE
, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J CIin Oncol
2006; 24: 2019–2027.
-
G.
Minckwitz,
M.
Untch,
J.
Blohmer,
S.
Costa,
H.
Eidtmann,
P.
Fasching,
B.
Gerber,
W.
Eiermann,
J.
Hilfrich,
J.
Huober,
C.
Jackisch,
M.
Kaufmann,
G.
Konecny,
C.
Denkert,
V.
Nekljudova,
K.
Mehta,
S.
Loibl
(2012)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
-
(
BanysM
KrawczykN
BeckerS
, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat
2012; 132: 121–129.21562707)
BanysM
KrawczykN
BeckerS
, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat
2012; 132: 121–129.21562707
BanysM
KrawczykN
BeckerS
, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat
2012; 132: 121–129.21562707,
BanysM
KrawczykN
BeckerS
, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat
2012; 132: 121–129.21562707
-
(
GoodmanChR
SpeersCW
. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions. Int J Radiat Oncol Biol Phys
2021; 109: 44–59.32882354)
GoodmanChR
SpeersCW
. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions. Int J Radiat Oncol Biol Phys
2021; 109: 44–59.32882354
GoodmanChR
SpeersCW
. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions. Int J Radiat Oncol Biol Phys
2021; 109: 44–59.32882354,
GoodmanChR
SpeersCW
. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions. Int J Radiat Oncol Biol Phys
2021; 109: 44–59.32882354
-
(
KlezlP
PospisilovaE
KolostovaK
, et al. Detection of circulating tumor cells in renal cell carcinoma: disease stage correlation and molecular characterization. Clin Med
2020; 9: 1–10.)
KlezlP
PospisilovaE
KolostovaK
, et al. Detection of circulating tumor cells in renal cell carcinoma: disease stage correlation and molecular characterization. Clin Med
2020; 9: 1–10.
KlezlP
PospisilovaE
KolostovaK
, et al. Detection of circulating tumor cells in renal cell carcinoma: disease stage correlation and molecular characterization. Clin Med
2020; 9: 1–10.,
KlezlP
PospisilovaE
KolostovaK
, et al. Detection of circulating tumor cells in renal cell carcinoma: disease stage correlation and molecular characterization. Clin Med
2020; 9: 1–10.
-
A.
Schneeweiss,
S.
Chia,
T.
Hickish,
Vernon
Harvey,
A.
Eniu,
R.
Hegg,
C.
Tausch,
J.
Seo,
Y.
Tsai,
J.
Ratnayake,
V.
Mcnally,
G.
Ross,
J.
Cortés
(2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
-
(
XenidisN
PerrakiM
KafousiM
, et al. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real time polymerase chain reaction in node negative breast cancer patients. J Clin Oncol
2006; 24: 3756–3762.16769987)
XenidisN
PerrakiM
KafousiM
, et al. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real time polymerase chain reaction in node negative breast cancer patients. J Clin Oncol
2006; 24: 3756–3762.16769987
XenidisN
PerrakiM
KafousiM
, et al. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real time polymerase chain reaction in node negative breast cancer patients. J Clin Oncol
2006; 24: 3756–3762.16769987,
XenidisN
PerrakiM
KafousiM
, et al. Predictive and prognostic value of peripheral blood cytokeratin 19 mRNA positive cells detected by real time polymerase chain reaction in node negative breast cancer patients. J Clin Oncol
2006; 24: 3756–3762.16769987
-
K.
Pachmann,
O.
Camara,
A.
Kavallaris,
S.
Krauspe,
Nele
Malarski,
M.
Gajda,
T.
Kroll,
C.
Jörke,
U.
Hammer,
A.
Altendorf-Hofmann,
C.
Rabenstein,
U.
Pachmann,
I.
Runnebaum,
K.
Höffken
(2008)
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
-
J.
Smerage,
W.
Barlow,
G.
Hortobagyi,
E.
Winer,
B.
Leyland-Jones,
G.
Srkalović,
S.
Tejwani,
A.
Schott,
M.
O'Rourke,
D.
Lew,
G.
Doyle,
J.
Gralow,
R.
Livingston,
D.
Hayes
(2014)
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 31
-
(
MillerK
O’NeillAM
DangCT
, et al. Bevacizumab (BV) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol
2014; 32(Suppl. 15): abstract 500.)
MillerK
O’NeillAM
DangCT
, et al. Bevacizumab (BV) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol
2014; 32(Suppl. 15): abstract 500.
MillerK
O’NeillAM
DangCT
, et al. Bevacizumab (BV) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol
2014; 32(Suppl. 15): abstract 500.,
MillerK
O’NeillAM
DangCT
, et al. Bevacizumab (BV) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol
2014; 32(Suppl. 15): abstract 500.
-
J.
Pierga,
F.
Bidard,
A.
Autret,
T.
Petit,
F.
Andre,
F.
Dalenc,
C.
Lévy,
J.
Ferrero,
G.
Romieu,
J.
Bonneterre,
F.
Lerebours,
T.
Bachelot,
P.
Kerbrat,
M.
Campone,
J.
Eymard,
M.
Mouret-Reynier,
J.
Gligorov,
A.
Hardy-Bessard,
A.
Lortholary,
P.
Soulié,
J.
Boher,
C.
Proudhon,
E.
Charafe-Jaufret,
J.
Lemonnier,
François
Bertucci,
P.
Viens
(2016)
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
Annals of Oncology, 28
-
(
FehmT
MüllerV
AktasB
, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010; 124: 403–412.20859679)
FehmT
MüllerV
AktasB
, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010; 124: 403–412.20859679
FehmT
MüllerV
AktasB
, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010; 124: 403–412.20859679,
FehmT
MüllerV
AktasB
, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010; 124: 403–412.20859679
-
(
SchneeweissA
ChiaS
HickishT
, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196)
SchneeweissA
ChiaS
HickishT
, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196
SchneeweissA
ChiaS
HickishT
, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196,
SchneeweissA
ChiaS
HickishT
, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol
2013; 24: 2278–2284.23704196
-
(
Von MinckwitzG
KummelS
VogelP
, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst
2008; 100: 552–562.18398094)
Von MinckwitzG
KummelS
VogelP
, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst
2008; 100: 552–562.18398094
Von MinckwitzG
KummelS
VogelP
, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst
2008; 100: 552–562.18398094,
Von MinckwitzG
KummelS
VogelP
, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst
2008; 100: 552–562.18398094
-
P.
Klézl,
Eliška
Pospíšilová,
K.
Kološtová,
Jindřich
Šonský,
Ondřej
Malý,
R.
Grill,
Ireneusz
Pawlak,
V.
Bobek
(2020)
Detection of Circulating Tumor Cells in Renal Cell Carcinoma: Disease Stage Correlation and Molecular Characterization
Journal of Clinical Medicine, 9
-
(
SerranoMJ
RoviraPS
Martínez-ZubiaurreI
, et al. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med
2012; 4: 43–48.23060920)
SerranoMJ
RoviraPS
Martínez-ZubiaurreI
, et al. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med
2012; 4: 43–48.23060920
SerranoMJ
RoviraPS
Martínez-ZubiaurreI
, et al. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med
2012; 4: 43–48.23060920,
SerranoMJ
RoviraPS
Martínez-ZubiaurreI
, et al. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med
2012; 4: 43–48.23060920
-
Sofia
Gkountela,
B.
Szczerba,
Cinzia
Donato,
N.
Aceto
(2016)
Recent advances in the biology of human circulating tumour cells and metastasis
ESMO Open, 1
-
D.
Mauri,
N.
Pavlidis,
J.
Ioannidis
(2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Journal of the National Cancer Institute, 97 3
-
M.
Cristofanilli,
G.
Budd,
M.
Ellis,
A.
Stopeck,
J.
Matera,
M.
Miller,
J.
Reuben,
G.
Doyle,
W.
Allard,
L.
Terstappen,
D.
Hayes
(2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
The New England journal of medicine, 351 8
-
(2021)
Circulating tumor cells and bevacizumab pharmacokinetics during neoadjuvant treatment combining chemotherapy and bevacizumab for early breast cancer: ancillary analysis of the AVASTEM trial. Cancers
-
O.
Camara,
M.
Rengsberger,
A.
Egbe,
A.
Koch,
M.
Gajda,
U.
Hammer,
C.
Jörke,
C.
Rabenstein,
M.
Untch,
K.
Pachmann
(2007)
The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 18 9
-
(
PaolettiC
ReganMM
LiuMC
, et al. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res
2017; 77(4_Suppl): Abstr. P1-01-01.)
PaolettiC
ReganMM
LiuMC
, et al. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res
2017; 77(4_Suppl): Abstr. P1-01-01.
PaolettiC
ReganMM
LiuMC
, et al. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res
2017; 77(4_Suppl): Abstr. P1-01-01.,
PaolettiC
ReganMM
LiuMC
, et al. Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial. Cancer Res
2017; 77(4_Suppl): Abstr. P1-01-01.
-
(
PeetersDJ
van DamPJ
Van den EyndenGG
, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer
2014; 110: 375–383.24366294)
PeetersDJ
van DamPJ
Van den EyndenGG
, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer
2014; 110: 375–383.24366294
PeetersDJ
van DamPJ
Van den EyndenGG
, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer
2014; 110: 375–383.24366294,
PeetersDJ
van DamPJ
Van den EyndenGG
, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer
2014; 110: 375–383.24366294
-
M.
Bredemeier,
P.
Edimiris,
M.
Tewes,
P.
Mach,
B.
Aktas,
D.
Schellbach,
Jenny
Wagner,
R.
Kimmig,
S.
Kasimir-Bauer
(2016)
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
Oncotarget, 7
-
F.
Bidard,
Y.
Rycke,
B.
Asselain,
P.
Cottu,
M.
Rodrigues,
R.
Lebofsky,
J.
Pierga
(2013)
Abstract OT1-1-10: CirCe T-DM1 phase II trial: Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1
Cancer Research, 73
-
(
CamaraO
RengsbergerM
EgbeA
, et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol
2007; 18: 1484–1492.17761704)
CamaraO
RengsbergerM
EgbeA
, et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol
2007; 18: 1484–1492.17761704
CamaraO
RengsbergerM
EgbeA
, et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol
2007; 18: 1484–1492.17761704,
CamaraO
RengsbergerM
EgbeA
, et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol
2007; 18: 1484–1492.17761704
-
A.
Lasa,
A.
Garcia,
C.
Alonso,
Pilar
Millet,
M.
Cornet,
T.
Cajal,
M.
Baiget,
A.
Barnadas
(2013)
Molecular Detection of Peripheral Blood Breast Cancer mRNA Transcripts as a Surrogate Biomarker for Circulating Tumor Cells
PLoS ONE, 8
-
(
van DalumG
van der StamGJ
TibbeAGJ
, et al. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol
2015; 46: 407–413.25339612)
van DalumG
van der StamGJ
TibbeAGJ
, et al. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol
2015; 46: 407–413.25339612
van DalumG
van der StamGJ
TibbeAGJ
, et al. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol
2015; 46: 407–413.25339612,
van DalumG
van der StamGJ
TibbeAGJ
, et al. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol
2015; 46: 407–413.25339612
-
C.
Paoletti,
Yufeng
Li,
Maria
Muñiz,
K.
Kidwell,
K.
Aung,
Dafydd
Thomas,
Martha
Brown,
V.
Abramson,
W.
Irvin,
N.
Lin,
Minetta
Liu,
R.
Nanda,
J.
Nangia,
A.
Storniolo,
T.
Traina,
C.
Vaklavas,
C.
Poznak,
A.
Wolff,
A.
Forero-Torres,
D.
Hayes
(2015)
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Clinical Cancer Research, 21
-
M.
Melisko,
A.
Forero,
R.
Bagley,
Joshua
Zhang,
L.
Vahdat
(2015)
Expression patterns of gpNMB in breast cancer (BC): Retrospective evaluation of tumor tissue from the phase II EMERGE study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 28_suppl
-
(
FrankenB
de GrootMR
MastboomWJ
, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res
2012; 14: R133.23088337)
FrankenB
de GrootMR
MastboomWJ
, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res
2012; 14: R133.23088337
FrankenB
de GrootMR
MastboomWJ
, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res
2012; 14: R133.23088337,
FrankenB
de GrootMR
MastboomWJ
, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res
2012; 14: R133.23088337
-
(
SmerageJB
BarlowWE
HortobagyiGN
, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol
2014; 32: 3483–3489.24888818)
SmerageJB
BarlowWE
HortobagyiGN
, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol
2014; 32: 3483–3489.24888818
SmerageJB
BarlowWE
HortobagyiGN
, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol
2014; 32: 3483–3489.24888818,
SmerageJB
BarlowWE
HortobagyiGN
, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol
2014; 32: 3483–3489.24888818
-
(
RiethdorfS
MüllerV
LoiblS
, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res
2017; 23: 5384–5393.28679772)
RiethdorfS
MüllerV
LoiblS
, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res
2017; 23: 5384–5393.28679772
RiethdorfS
MüllerV
LoiblS
, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res
2017; 23: 5384–5393.28679772,
RiethdorfS
MüllerV
LoiblS
, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res
2017; 23: 5384–5393.28679772
-
M.
Wallwiener,
A.
Hartkopf,
S.
Riethdorf,
J.
Nees,
M.
Sprick,
B.
Schönfisch,
F.
Taran,
J.
Heil,
C.
Sohn,
K.
Pantel,
A.
Trumpp,
A.
Schneeweiss
(2015)
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
BMC Cancer, 15
-
S.
Vafaei,
R.
Roudi,
Z.
Madjd,
A.
Aref,
Marzieh
Ebrahimi
(2020)
Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer
Cancer Cell International, 20
-
(2014)
clusters are oligoclonal precursors of breast cancer metastasis
-
J.
Sparano,
A.
O'neill,
K.
Alpaugh,
A.
Wolff,
D.
Northfelt,
C.
Dang,
G.
Sledge,
K.
Miller
(2018)
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
JAMA Oncology, 4
-
(
WallwienerM
HartkopfAD
RiethdorfS
, et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer
2015; 15: 403.25972110)
WallwienerM
HartkopfAD
RiethdorfS
, et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer
2015; 15: 403.25972110
WallwienerM
HartkopfAD
RiethdorfS
, et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer
2015; 15: 403.25972110,
WallwienerM
HartkopfAD
RiethdorfS
, et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer
2015; 15: 403.25972110
-
(
MolloyTJ
DevrieseLA
HelgasonHH
, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer
2011; 104: 1913–1919.21587256)
MolloyTJ
DevrieseLA
HelgasonHH
, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer
2011; 104: 1913–1919.21587256
MolloyTJ
DevrieseLA
HelgasonHH
, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer
2011; 104: 1913–1919.21587256,
MolloyTJ
DevrieseLA
HelgasonHH
, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer
2011; 104: 1913–1919.21587256
-
Sang‐Kwon
Lee,
Gil-Sung
Kim,
Yu
Wu,
Dong-Joo
Kim,
Yao
Lu,
Minsuk
Kwak,
Lin
Han,
Jung-Hwan
Hyung,
Jin-Kyeong
Seol,
Chantal
Sander,
Anjelica
Gonzalez,
Jie
Li,
R.
Fan
(2012)
Nanowire substrate-based laser scanning cytometry for quantitation of circulating tumor cells.
Nano letters, 12 6
-
B.
Aktas,
V.
Müller,
M.
Tewes,
Julia
Zeitz,
S.
Kasimir-Bauer,
C.
Loehberg,
B.
Rack,
A.
Schneeweiss,
T.
Fehm
(2011)
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
Gynecologic oncology, 122 2
-
(
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
2005; 365: 1687–1717.15894097)
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
2005; 365: 1687–1717.15894097
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
2005; 365: 1687–1717.15894097,
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
2005; 365: 1687–1717.15894097
-
O.
Bitisik,
P.
Saip,
Sezer
Saglam,
D.
Derin,
N.
Dalay
(2010)
Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer.
Genetics and molecular research : GMR, 9 1
-
J.
Zhang,
Q.
Yao,
J-H
Wang,
H.
Wang,
Q.
Fan,
R.
Ling,
J.
Yi,
L.
Wang
(2015)
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.
Genetics and molecular research : GMR, 14 1
-
(
MansooriM
RoudiR
AbbasiA
, et al. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol
2019; 109: 25–35.31075227)
MansooriM
RoudiR
AbbasiA
, et al. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol
2019; 109: 25–35.31075227
MansooriM
RoudiR
AbbasiA
, et al. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol
2019; 109: 25–35.31075227,
MansooriM
RoudiR
AbbasiA
, et al. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol
2019; 109: 25–35.31075227
-
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
-
(
OrsiG
BarboliniM
FicarraG
, et al. GD2 expression in breast cancer. Oncotarget
2017; 8: 31592–31600.28415563)
OrsiG
BarboliniM
FicarraG
, et al. GD2 expression in breast cancer. Oncotarget
2017; 8: 31592–31600.28415563
OrsiG
BarboliniM
FicarraG
, et al. GD2 expression in breast cancer. Oncotarget
2017; 8: 31592–31600.28415563,
OrsiG
BarboliniM
FicarraG
, et al. GD2 expression in breast cancer. Oncotarget
2017; 8: 31592–31600.28415563
-
E.
Trapp,
W.
Janni,
C.
Schindlbeck,
J.
Jückstock,
U.
Andergassen,
A.
Gregorio,
M.
Alunni-Fabbroni,
M.
Tzschaschel,
A.
Polasik,
J.
Koch,
T.
Friedl,
P.
Fasching,
L.
Haeberle,
T.
Fehm,
A.
Schneeweiss,
M.
Beckmann,
K.
Pantel,
V.
Mueller,
B.
Rack,
C.
Scholz
(2018)
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
Journal of the National Cancer Institute, 111 4
-
B.
Franken,
M.
Groot,
W.
Mastboom,
I.
Vermes,
J.
Palen,
A.
Tibbe,
L.
Terstappen
(2012)
Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer
Breast Cancer Research : BCR, 14
-
(
SABCS.Org [homepage on the Internet]. The San Antonio Breast Cancer Symposium, December. http://www.sabcs.org (2013, accessed 21 February 2014).)
SABCS.Org [homepage on the Internet]. The San Antonio Breast Cancer Symposium, December. http://www.sabcs.org (2013, accessed 21 February 2014).
SABCS.Org [homepage on the Internet]. The San Antonio Breast Cancer Symposium, December. http://www.sabcs.org (2013, accessed 21 February 2014).,
SABCS.Org [homepage on the Internet]. The San Antonio Breast Cancer Symposium, December. http://www.sabcs.org (2013, accessed 21 February 2014).
-
(
MüllerV
StahmannN
RiethdorfS
, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res
2005; 11: 3678–3685.15897564)
MüllerV
StahmannN
RiethdorfS
, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res
2005; 11: 3678–3685.15897564
MüllerV
StahmannN
RiethdorfS
, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res
2005; 11: 3678–3685.15897564,
MüllerV
StahmannN
RiethdorfS
, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res
2005; 11: 3678–3685.15897564
-
B.
Rack,
C.
Schindlbeck,
J.
Jückstock,
U.
Andergassen,
P.
Hepp,
T.
Zwingers,
T.
Friedl,
R.
Lorenz,
H.
Tesch,
P.
Fasching,
T.
Fehm,
A.
Schneeweiss,
W.
Lichtenegger,
M.
Beckmann,
K.
Friese,
K.
Pantel,
W.
Janni
(2014)
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
JNCI Journal of the National Cancer Institute, 106
-
(
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560)
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560,
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560
-
O.
Abe,
R.
Abe,
K.
Enomoto,
K.
Kikuchi,
H.
Koyama,
H.
Masuda,
Y.
Nomura,
K.
Sakai,
K.
Sugimachi,
T.
Tominaga,
J.
Uchino,
M.
Yoshida,
J.
Haybittle,
C.
Davies,
V.
Harvey,
TM
Holdaway,
R.
Kay,
B.
Mason,
J.
Forbes,
N.
Wilcken,
M.
Gnant,
R.
Jakesz,
M.
Ploner,
H.
Yosef,
C.
Focan,
J.
Lobelle,
U.
Peek,
G.
Oates,
J.
Powell,
M.
Durand,
L.
Mauriac,
A.
Leo,
S.
Dolci,
M.
Piccart,
M.
Masood,
D.
Parker,
J.
Price,
P.
Hupperets,
S.
Jackson,
J.
Ragaz,
D.
Berry,
G.
Broadwater,
C.
Cirrincione,
H.
Muss,
L.
Norton,
R.
Weiss,
H.
Abu‐Zahra,
S.
Portnoj,
M.
Baum,
J.
Cuzick,
J.
Houghton,
D.
Riley,
NH
Gordon,
H.
Davis,
A.
Beatrice,
J.
Mihura,
A.
Naja,
Y.
Lehingue,
P.
Romestaing,
JB
Dubois,
T.
Delozier,
J.
Macé-Lesec’h,
P.
Rambert,
O.
Andrysek,
J.
Barkmanova,
Owen,
P.
Meier,
A.
Howell,
G.
Ribeiro,
R.
Swindell,
R.
Alison,
J.
Boreham,
M.
Clarke,
R.
Collins,
S.
Darby,
P.
Elphinstone,
Evans,
J.
Godwin,
R.
Gray,
C.
Harwood,
C.
Hicks,
S.
James,
E.
Mackinnon,
P.
Mcgale,
T.
McHugh,
G.
Mead,
R.
Peto,
Y.
Wang,
J.
Albano,
Cf
Oliveira,
H.
Gervásio,
J.
Gordilho,
H.
Johansen,
H.
Mouridsen,
R.
Gelman,
Harris,
I.
Henderson,
Claire
Shapiro,
K.
Andersen,
C.
Axelsson,
M.
Blichert‐Toft,
S.
Møller,
J.
Overgaard,
M.
Overgaard,
C.
Rose,
B.
Cartensen,
T.
Palshof,
H.
Trampisch,
O.
Dalesio,
D.
Vries,
S.
Rodenhuis,
H.
Tinteren,
R.
Comis,
N.
Davidson,
N.
Robert,
G.
Sledge,
D.
Tormey,
W.
Wood,
D.
Cameron,
U.
Chetty,
P.
Forrest,
W.
Jack,
J.
Rossbach,
J.
Klijn,
A.
Treurniet‐Donker,
W.
Putten,
Alberto
Costa,
U.
Veronesi,
H.
Bartelink,
L.
Duchateau,
C.
Legrand,
R.
Sylvester,
J.
Hage,
C.
Velde,
M.
Cunningham,
R.
Catalano,
R.
Creech,
J.
Bonneterre,
P.
Fargeot,
P.
Fumoleau,
P.
Kerbrat,
M.
Namer,
W.
Jonat,
M.
Kaufmann,
M.
Schumacher,
G.
Minckwitz,
G.
Bastert,
H.
Rauschecker,
R.
Sauer,
W.
Sauerbrei,
A.
Schauer,
A.
Schryver,
L.
Vakaet,
M.
Belfiglio,
A.
Nicolucci,
F.
Pellegrini,
M.
Sacco,
M.
Valentini,
C.
McArdle,
D.
Smith,
E.
Galligioni,
F.
Boccardo,
A.
Rubagotti,
D.
Dent,
C.
Gudgeon,
A.
Hacking,
A.
Erazo,
J.
Medina,
M.
Izuo,
Y.
Morishita,
H.
Takei,
I.
Fentiman,
J.
Hayward,
R.
Rubens,
D.
Skilton,
H.
Graeff,
F.
Jänicke,
C.
Meisner,
H.
Scheurlen,
D.
Fournier,
U.
Dafni,
G.
Fountzilas,
P.
Klefstrom,
C.
Blomqvist,
T.
Saarto,
R.
Margreiter,
B.
Asselain,
R.
Salmon,
Vilcoq,
R.
Arriagada,
C.
Hill,
A.
Laplanche,
M.
Lê,
M.
Spielmann,
P.
Bruzzi,
E.
Montanaro,
R.
Rosso,
Sertoli,
M.
Venturini,
D.
Amadori,
J.
Benraadt,
M.
Kooi,
A.
Velde,
J.
Dongen,
J.
Vermorken,
M.
Castiglione,
F.
Cavalli,
A.
Coates,
J.
Collins,
J.
Forbes,
R.
Gelber,
A.
Goldhirsch,
J.
Lindtner,
K.
Price,
C.
Rudenstam,
H.
Senn,
J.
Bliss,
C.
Chilvers,
R.
Coombes,
E.
Hall,
M.
Marty,
R.
Borovik,
G.
Brufman,
H.
Hayat,
E.
Robinson,
N.
Wigler,
G.
Bonadonna,
T.
Camerini,
G.
Palo,
M.
Vecchio,
F.
Formelli,
P.
Valagussa,
A.
Martoni,
F.
Pannuti,
G.
Cocconi,
A.
Colozza,
R.
Camisa,
K.
Aogi,
S.
Takashima,
T.
Ikeda,
K.
Inokuchi,
K.
Sawa,
H.
Sonoo,
S.
Korzeniowski,
J.
Skołyszewski,
M.
Ogawa,
J.
Yamashita,
J.
Bonté,
R.
Christiaens,
R.
Paridaens,
W.
Boegart,
P.
Martin,
S.
Romain,
T.
Hakes,
C.
Hudis,
R.
Wittes,
G.
Giokas,
D.
Kondylis,
B.
Lissaios,
R.
Huerta,
MG
Sainz,
R.
Altemus,
K.
Cowan,
D.
Danforth,
A.
Lichter,
M.
Lippman,
J.
O’Shaughnessy,
L.
Pierce,
S.
Steinberg,
D.
Venzon,
J.
Zujewski,
A.
Paradiso,
M.
Lena,
F.
Schittulli,
J.
Myles,
J.
Pater,
K.
Pritchard,
S.
Anderson,
G.
Bass,
Andrew
Brown,
J.
Bryant,
J.
Costantino,
J.
Dignam,
B.
Fisher,
C.
Redmond,
S.
Wieand,
N.
Wolmark,
I.
Jackson,
M.
Palmer,
J.
Ingle,
V.
Suman,
N.
Bengtsson,
H.
Jonsson,
L.
Larsson,
J.
Lythgoe,
M.
Kissin,
B.
Erikstein,
E.
Hannisdal,
Abby
Jacobsen,
J.
Varhaug,
S.
Gundersen,
M.
Hauer-Jensen,
H.
Høst,
R.
Nissen-Meyer,
R.
Blamey,
A.
Mitchell,
D.
Morgan,
J.
Robertson,
M.
Palma,
G.
Mathé,
J.
Misset,
R.
Clark,
M.
Levine,
K.
Morimoto,
Y.
Takatsuka,
E.
Crossley,
A.
Harris,
D.
Talbot,
Marianne
Taylor,
B.
Blasio,
Ivanov,
Semiglazov,
J.
Brockschmidt,
Cooper,
H.
Ueo,
C.
Falkson,
R.
a'Hern,
S.
Ashley,
T.
Powles,
I.
Smith,
Yarnold,
Gazet
Jc,
N.
Cocoran,
N.
Deshpande,
L.
Martino,
P.
Douglas,
A.
Lindtner,
G.
Notter,
Ajs
Bryant,
G.
Ewing,
L.
Firth,
J.
Krushen-Kosloski,
L.
Foster,
W.
George,
H.
Stewart,
P.
Stroner,
P.
Malmström,
T.
Möller,
S.
Rydén,
Tengrup,
L.
Tennvall-Nittby,
J.
Carstenssen,
M.
Dufmats,
T.
Hatschek,
B.
Nordenskjöld,
M.
Söderberg,
J.
Carpenter,
K.
Albain,
James
Crowley,
S.
Green,
S.
Martino,
C.
Osborne,
P.
Ravdin,
U.
Glas,
U.
Johansson,
L.
Rutqvist,
T.
Singnomklao,
A.
Wallgren,
R.
Maibach,
B.
Thürlimann,
H.
Brenner,
A.
Hercbergs,
M.
Yoshimoto,
G.
Deboer,
A.
Paterson,
J.
Meakin,
T.
Panzarella,
Y.
Shan,
Y.
Shao,
Y
Wang,
DB
Zhao,
Zm
Chen,
HC
Pan,
J.
Bahi,
M.
Reid,
M.
Spittle,
Gp
Deutsch,
F.
Senanayake,
D.
Kwong,
A.
Bianco,
C.
Carlomagno,
M.
Laurentiis,
S.
Placido,
A.
Buzdar,
Thomas
Smith,
J.
Bergh,
L.
Holmberg,
G.
Liljegren,
J.
Nilsson,
M.
Seifert,
P.
Sevelda,
C.
Zielinsky,
R.
Buchanan,
M.
Cross,
G.
Royle,
J.
Dunn,
R.
Hills,
M.
Lee,
J.
Morrison,
D.
Spooner,
A.
Litton,
R.
Chlebowski,
H.
Caffier,
Ebctcg
(2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
The Lancet, 365
-
S.
Riethdorf,
V.
Müller,
Liling
Zhang,
T.
Rau,
S.
Loibl,
M.
Komor,
M.
Roller,
J.
Huober,
T.
Fehm,
I.
Schrader,
J.
Hilfrich,
F.
Holms,
H.
Tesch,
H.
Eidtmann,
M.
Untch,
G.
Minckwitz,
K.
Pantel
(2010)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Clinical Cancer Research, 16
-
(
BidardFC
de RyckeY
AsselainB
, et al. CirCe T-DM1 phase II trial: assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1. Cancer Res
2013; 73(Suppl. 24): abstract OT1-1-10.)
BidardFC
de RyckeY
AsselainB
, et al. CirCe T-DM1 phase II trial: assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1. Cancer Res
2013; 73(Suppl. 24): abstract OT1-1-10.
BidardFC
de RyckeY
AsselainB
, et al. CirCe T-DM1 phase II trial: assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1. Cancer Res
2013; 73(Suppl. 24): abstract OT1-1-10.,
BidardFC
de RyckeY
AsselainB
, et al. CirCe T-DM1 phase II trial: assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1. Cancer Res
2013; 73(Suppl. 24): abstract OT1-1-10.
-
(
TrappE
JanniW
SchindlbeckCh
, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst
2019; 111: 380–387.30312434)
TrappE
JanniW
SchindlbeckCh
, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst
2019; 111: 380–387.30312434
TrappE
JanniW
SchindlbeckCh
, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst
2019; 111: 380–387.30312434,
TrappE
JanniW
SchindlbeckCh
, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst
2019; 111: 380–387.30312434
-
(
LasaA
GarciaA
AlonsoC
, et al. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One
2013; 8: e74079.24058517)
LasaA
GarciaA
AlonsoC
, et al. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One
2013; 8: e74079.24058517
LasaA
GarciaA
AlonsoC
, et al. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One
2013; 8: e74079.24058517,
LasaA
GarciaA
AlonsoC
, et al. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One
2013; 8: e74079.24058517
-
R.
Sabatier,
J.
Pierga,
H.
Curé,
Rakan
Abulnaja,
E.
Lambaudie,
F.
Bidard,
J.
Extra,
P.
Sfumato,
A.
Gonçalves
(2021)
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
Cancers, 13
-
N.
Xenidis,
M.
Perraki,
S.
Apostolaki,
S.
Agelaki,
K.
Kalbakis,
N.
Vardakis,
A.
Kalykaki,
A.
Xyrafas,
S.
Kakolyris,
D.
Mavroudis,
V.
Georgoulias
(2013)
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
British Journal of Cancer, 108
-
F.
Bidard,
S.
Michiels,
S.
Riethdorf,
V.
Mueller,
L.
Esserman,
A.
Lucci,
B.
Naume,
J.
Horiguchi,
R.
Gisbert-Criado,
S.
Sleijfer,
M.
Toi,
J.
García-Saenz,
A.
Hartkopf,
D.
Generali,
F.
Rothé,
J.
Smerage,
L.
Muinelo-Romay,
J.
Stebbing,
P.
Viens,
M.
Magbanua,
C.
Hall,
O.
Engebraaten,
D.
Takata,
J.
Vidal-Martínez,
W.
Onstenk,
N.
Fujisawa,
E.
Díaz-Rubio,
F.
Taran,
M.
Cappelletti,
M.
Ignatiadis,
C.
Proudhon,
D.
Wolf,
J.
Bauldry,
E.
Borgen,
R.
Nagaoka,
V.
Carañana,
J.
Kraan,
M.
Maestro,
S.
Brucker,
K.
Weber,
F.
Reyal,
Dominic
Amara,
M.
Karhade,
R.
Mathiesen,
H.
Tokiniwa,
A.
Llombart-Cussac,
A.
Meddis,
P.
Blanche,
K.
d'Hollander,
P.
Cottu,
John
Park,
S.
Loibl,
A.
Latouche,
J.
Pierga,
K.
Pantel
(2018)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
JNCI: Journal of the National Cancer Institute, 110
-
(
VafaeiS
RoudiR
MadjdZ
, et al. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int
2020; 20: 1–15.31908598)
VafaeiS
RoudiR
MadjdZ
, et al. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int
2020; 20: 1–15.31908598
VafaeiS
RoudiR
MadjdZ
, et al. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int
2020; 20: 1–15.31908598,
VafaeiS
RoudiR
MadjdZ
, et al. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int
2020; 20: 1–15.31908598
-
(
AktasB
MüllerV
TewesM
, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol
2011; 122: 356–360.21605893)
AktasB
MüllerV
TewesM
, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol
2011; 122: 356–360.21605893
AktasB
MüllerV
TewesM
, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol
2011; 122: 356–360.21605893,
AktasB
MüllerV
TewesM
, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol
2011; 122: 356–360.21605893
-
S.
Cocco,
M.
Piezzo,
A.
Calabrese,
D.
Cianniello,
R.
Caputo,
V.
Lauro,
G.
Fusco,
G.
Gioia,
M.
Licenziato,
M.
Laurentiis
(2020)
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
International Journal of Molecular Sciences, 21
-
(
GkountelaS
SzczerbaB
DonatoC
, et al. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open
2016; 1: 1–9.)
GkountelaS
SzczerbaB
DonatoC
, et al. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open
2016; 1: 1–9.
GkountelaS
SzczerbaB
DonatoC
, et al. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open
2016; 1: 1–9.,
GkountelaS
SzczerbaB
DonatoC
, et al. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open
2016; 1: 1–9.
-
(
BitisikO
SaipP
SaglamS
, et al. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res
2009; 9: 97–106.)
BitisikO
SaipP
SaglamS
, et al. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res
2009; 9: 97–106.
BitisikO
SaipP
SaglamS
, et al. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res
2009; 9: 97–106.,
BitisikO
SaipP
SaglamS
, et al. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res
2009; 9: 97–106.
-
G.
Minckwitz,
W.
Schmitt,
S.
Loibl,
B.
Müller,
J.
Blohmer,
B.
Sinn,
H.
Eidtmann,
W.
Eiermann,
B.
Gerber,
H.
Tesch,
J.
Hilfrich,
J.
Huober,
T.
Fehm,
J.
Barinoff,
T.
Rüdiger,
E.
Erbstoesser,
P.
Fasching,
T.
Karn,
V.
Müller,
C.
Jackisch,
C.
Denkert
(2013)
Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Clinical Cancer Research, 19
-
(2010)
Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III 12. GeparQuattro study
-
N.
Xenidis,
M.
Perraki,
M.
Kafousi,
S.
Apostolaki,
I.
Bolonaki,
A.
Stathopoulou,
K.
Kalbakis,
N.
Androulakis,
C.
Kouroussis,
T.
Pallis,
C.
Christophylakis,
K.
Argyraki,
E.
Lianidou,
S.
Stathopoulos,
V.
Georgoulias,
D.
Mavroudis
(2006)
Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 23
-
(
BardiaA
MayerIA
VahdatLT
, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med
2019; 380: 741–751.30786188)
BardiaA
MayerIA
VahdatLT
, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med
2019; 380: 741–751.30786188
BardiaA
MayerIA
VahdatLT
, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med
2019; 380: 741–751.30786188,
BardiaA
MayerIA
VahdatLT
, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med
2019; 380: 741–751.30786188
-
(
YardleyDA
WeaverR
MeliskoME
, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol
2015; 33: 1609–1619.25847941)
YardleyDA
WeaverR
MeliskoME
, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol
2015; 33: 1609–1619.25847941
YardleyDA
WeaverR
MeliskoME
, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol
2015; 33: 1609–1619.25847941,
YardleyDA
WeaverR
MeliskoME
, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol
2015; 33: 1609–1619.25847941
-
V.
Müller,
Nicole
Stahmann,
S.
Riethdorf,
T.
Rau,
T.
Zabel,
A.
Goetz,
F.
Jänicke,
K.
Pantel
(2005)
Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity
Clinical Cancer Research, 11
-
(
BidardF
BaffertS
HajageD
, et al. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res
2012; 72(Suppl. 24): abstract OT3-4-06.)
BidardF
BaffertS
HajageD
, et al. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res
2012; 72(Suppl. 24): abstract OT3-4-06.
BidardF
BaffertS
HajageD
, et al. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res
2012; 72(Suppl. 24): abstract OT3-4-06.,
BidardF
BaffertS
HajageD
, et al. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res
2012; 72(Suppl. 24): abstract OT3-4-06.
-
(
PachmannK
CamaraO
KavallarisA
, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol
2008; 26: 1208–1215.18323545)
PachmannK
CamaraO
KavallarisA
, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol
2008; 26: 1208–1215.18323545
PachmannK
CamaraO
KavallarisA
, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol
2008; 26: 1208–1215.18323545,
PachmannK
CamaraO
KavallarisA
, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol
2008; 26: 1208–1215.18323545
-
A.
Lavrov,
Zh.
Zubtsova,
D.
Zubtsov,
M.
Frolova,
E.
Ignatova,
M.
Skrypnikova,
E.
Malysheva,
E.
Legchenko,
A.
Petrovskii,
I.
Utyashev,
S.
Tyulyandin,
D.
Gol’dshtein
(2014)
Analysis of Circulating Tumor Cells in Patients with Triple Negative Breast Cancer during Preoperative Chemotherapy
Bulletin of Experimental Biology and Medicine, 157
-
Liling
Zhang,
S.
Riethdorf,
Gang
Wu,
Tao
Wang,
Kunyu
Yang,
G.
Peng,
Junli
Liu,
K.
Pantel
(2012)
Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer
Clinical Cancer Research, 18
-
(
CristofanilliM
BuddG
EllisM
, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med
2004; 351: 781–791.15317891)
CristofanilliM
BuddG
EllisM
, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med
2004; 351: 781–791.15317891
CristofanilliM
BuddG
EllisM
, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med
2004; 351: 781–791.15317891,
CristofanilliM
BuddG
EllisM
, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med
2004; 351: 781–791.15317891
-
(
MegoM
GiordanoA
De GiorgiU
, et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res
2015; 17: 2.25572591)
MegoM
GiordanoA
De GiorgiU
, et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res
2015; 17: 2.25572591
MegoM
GiordanoA
De GiorgiU
, et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res
2015; 17: 2.25572591,
MegoM
GiordanoA
De GiorgiU
, et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res
2015; 17: 2.25572591
-
(
ZhangJL
YaoQ
ChenY
WangJH
, et al. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer. Genet Mol Res
2015; 14: 2099–2103.25867356)
ZhangJL
YaoQ
ChenY
WangJH
, et al. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer. Genet Mol Res
2015; 14: 2099–2103.25867356
ZhangJL
YaoQ
ChenY
WangJH
, et al. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer. Genet Mol Res
2015; 14: 2099–2103.25867356,
ZhangJL
YaoQ
ChenY
WangJH
, et al. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer. Genet Mol Res
2015; 14: 2099–2103.25867356
-
J.
Hage,
C.
Velde,
J.
Julien,
M.
Tubiana-Hulin,
Cecile
Vandervelden,
L.
Duchateau
(2001)
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 22
-
(
BaselgaJ
BradburyI
EidtmannH
, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet
2012; 379: 633–640.22257673)
BaselgaJ
BradburyI
EidtmannH
, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet
2012; 379: 633–640.22257673
BaselgaJ
BradburyI
EidtmannH
, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet
2012; 379: 633–640.22257673,
BaselgaJ
BradburyI
EidtmannH
, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet
2012; 379: 633–640.22257673
-
Sumeyye
Cavdarli,
S.
Groux-Degroote,
P.
Delannoy
(2019)
Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors
Biomolecules, 9
-
(
CavdarliS
Groux-DegrooteS
DelannoyP
. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules
2019; 9: 311.)
CavdarliS
Groux-DegrooteS
DelannoyP
. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules
2019; 9: 311.
CavdarliS
Groux-DegrooteS
DelannoyP
. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules
2019; 9: 311.,
CavdarliS
Groux-DegrooteS
DelannoyP
. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules
2019; 9: 311.
-
(2014)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of European studies
-
J.
Pierga,
F.
Bidard,
C.
Mathiot,
E.
Brain,
S.
Delaloge,
S.
Giachetti,
P.
Crémoux,
R.
Salmon,
A.
Vincent-Salomon,
M.
Marty
(2008)
Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
Clinical Cancer Research, 14
-
(
LiuY
LiuQ
WangT
, et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer
2013; 13: 202.23617715)
LiuY
LiuQ
WangT
, et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer
2013; 13: 202.23617715
LiuY
LiuQ
WangT
, et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer
2013; 13: 202.23617715,
LiuY
LiuQ
WangT
, et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer
2013; 13: 202.23617715
-
G.
Minckwitz,
H.
Eidtmann,
M.
Rezai,
P.
Fasching,
H.
Tesch,
H.
Eggemann,
I.
Schrader,
K.
Kittel,
C.
Hanusch,
R.
Kreienberg,
C.
Solbach,
B.
Gerber,
C.
Jackisch,
G.
Kunz,
J.
Blohmer,
J.
Huober,
M.
Hauschild,
T.
Fehm,
B.
Müller,
C.
Denkert,
S.
Loibl,
V.
Nekljudova,
M.
Untch
(2012)
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
The New England journal of medicine, 366 4
-
K.
Livak,
Thomas
Schmittgen
(2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods, 25 4
-
S.
Riethdorf,
V.
Müller,
S.
Loibl,
V.
Nekljudova,
K.
Weber,
J.
Huober,
T.
Fehm,
I.
Schrader,
J.
Hilfrich,
F.
Holms,
H.
Tesch,
C.
Schem,
G.
Minckwitz,
M.
Untch,
K.
Pantel
(2017)
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Clinical Cancer Research, 23
-
(
ZhangL
RiethdorfS
WuG
, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res
2012; 18: 5701–5710.22908097)
ZhangL
RiethdorfS
WuG
, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res
2012; 18: 5701–5710.22908097
ZhangL
RiethdorfS
WuG
, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res
2012; 18: 5701–5710.22908097,
ZhangL
RiethdorfS
WuG
, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res
2012; 18: 5701–5710.22908097
-
(
AcetoN
BardiaA
MiyamotoDT
, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell
2014; 158: 1110–1122.25171411)
AcetoN
BardiaA
MiyamotoDT
, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell
2014; 158: 1110–1122.25171411
AcetoN
BardiaA
MiyamotoDT
, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell
2014; 158: 1110–1122.25171411,
AcetoN
BardiaA
MiyamotoDT
, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell
2014; 158: 1110–1122.25171411
-
G.
Minckwitz,
S.
Kümmel,
P.
Vogel,
C.
Hanusch,
H.
Eidtmann,
J.
Hilfrich,
B.
Gerber,
J.
Huober,
S.
Costa,
C.
Jackisch,
S.
Loibl,
K.
Mehta,
M.
Kaufmann
(2008)
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
Journal of the National Cancer Institute, 100 8
-
M.
Banyś,
N.
Krawczyk,
S.
Becker,
J.
Jakubowska,
A.
Staebler,
D.
Wallwiener,
T.
Fehm,
R.
Rothmund
(2011)
The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer
Breast Cancer Research and Treatment, 132
-
K.
Miller,
A.
O'neill,
C.
Dang,
D.
Northfelt,
W.
Gradishar,
L.
Goldstein,
I.
Mayer,
A.
Brufsky,
Stuart
Bloom,
J.
Sparano,
Amye
Tevaarwerk,
K.
Fox,
C.
Hendricks,
E.
Balcueva,
G.
Sledge
(2014)
Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.
Journal of Clinical Oncology, 32
-
G.
Orsi,
M.
Barbolini,
G.
Ficarra,
G.
Tazzioli,
P.
Manni,
Tiziana
Petrachi,
Ilenia
Mastrolia,
E.
Orvieto,
C.
Spano,
M.
Prapa,
S.
Kaleci,
R.
D'amico,
V.
Guarneri,
M.
Dieci,
S.
Cascinu,
P.
Conte,
F.
Piacentini,
M.
Dominici
(2017)
GD2 expression in breast cancer
Oncotarget, 8
-
(
MauriD
PavlidisN
IoannidisJP
. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst
2005; 97: 188–194.15687361)
MauriD
PavlidisN
IoannidisJP
. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst
2005; 97: 188–194.15687361
MauriD
PavlidisN
IoannidisJP
. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst
2005; 97: 188–194.15687361,
MauriD
PavlidisN
IoannidisJP
. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst
2005; 97: 188–194.15687361
-
G.
Dalum,
Gert
Stam,
A.
Tibbe,
B.
Franken,
W.
Mastboom,
I.
Vermes,
M.
Groot,
L.
Terstappen
(2015)
Circulating tumor cells before and during follow-up after breast cancer surgery.
International journal of oncology, 46 1
-
(
LavrovAV1
ZubtsovaZhI
ZubtsovDA
, et al. Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy. Bull Exp Biol Med
2014; 157: 159–161.24913582)
LavrovAV1
ZubtsovaZhI
ZubtsovDA
, et al. Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy. Bull Exp Biol Med
2014; 157: 159–161.24913582
LavrovAV1
ZubtsovaZhI
ZubtsovDA
, et al. Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy. Bull Exp Biol Med
2014; 157: 159–161.24913582,
LavrovAV1
ZubtsovaZhI
ZubtsovDA
, et al. Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy. Bull Exp Biol Med
2014; 157: 159–161.24913582
-
H.
Bear,
S.
Anderson,
Roy
Smith,
C.
Geyer,
E.
Mamounas,
B.
Fisher,
A.
Brown,
A.
Robidoux,
R.
Margolese,
M.
Kahlenberg,
S.
Paik,
A.
Soran,
D.
Wickerham,
N.
Wolmark
(2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
-
D.
Peeters,
P.
Dam,
G.
Eynden,
A.
Rutten,
H.
Wuyts,
Lieven
Pouillon,
Marc
Peeters,
Patrick
Pauwels,
S.
Laere,
P.
Dam,
P.
Vermeulen,
Luc
Dirix
(2013)
Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
British Journal of Cancer, 110
-
(2017)
Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial
-
B.
Nazha,
C.
Inal,
T.
Owonikoko
(2020)
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Frontiers in Oncology, 10
-
T.
Sørlie,
R.
Tibshirani,
Joel
Parker,
T.
Hastie,
J.
Marron,
A.
Nobel,
Shibing
Deng,
H.
Johnsen,
Robert
Pesich,
S.
Geisler,
J.
Demeter,
C.
Perou,
P.
Lønning,
P.
Brown,
A.
Børresen-Dale,
D.
Botstein
(2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
Proceedings of the National Academy of Sciences of the United States of America, 100
-
(
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
2003; 100: 8418–8423.12829800)
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
2003; 100: 8418–8423.12829800
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
2003; 100: 8418–8423.12829800,
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
2003; 100: 8418–8423.12829800
-
N.
Krawczyk,
M.
Banyś,
H.
Neubauer,
E.
Solomayer,
C.
Gall,
M.
Hahn,
S.
Becker,
R.
Bachmann,
D.
Wallwiener,
T.
Fehm
(2009)
HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor.
Anticancer research, 29 10
-
(
LivakKJ
SchmittgenTD
. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001; 25: 402–408.11846609)
LivakKJ
SchmittgenTD
. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001; 25: 402–408.11846609
LivakKJ
SchmittgenTD
. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001; 25: 402–408.11846609,
LivakKJ
SchmittgenTD
. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001; 25: 402–408.11846609
-
(
GianniL
PienkowskiT
ImYH
, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol
2012; 13: 25–32.22153890)
GianniL
PienkowskiT
ImYH
, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol
2012; 13: 25–32.22153890
GianniL
PienkowskiT
ImYH
, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol
2012; 13: 25–32.22153890,
GianniL
PienkowskiT
ImYH
, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol
2012; 13: 25–32.22153890
-
(
SikovWM
BerryDA
PerouCM
, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol
2015; 33: 13–21.25092775)
SikovWM
BerryDA
PerouCM
, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol
2015; 33: 13–21.25092775
SikovWM
BerryDA
PerouCM
, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol
2015; 33: 13–21.25092775,
SikovWM
BerryDA
PerouCM
, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol
2015; 33: 13–21.25092775
-
F.
Bidard,
L.
Belin,
S.
Delaloge,
F.
Lerebours,
C.
Ngô,
F.
Reyal,
S.
Alran,
S.
Giacchetti,
M.
Marty,
R.
Lebofsky,
J.
Pierga
(2013)
Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
International Journal of Breast Cancer, 2013
-
(
KrawczykN
BanysM
NeubauerH
, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res
2009; 29: 4019–4024.19846945)
KrawczykN
BanysM
NeubauerH
, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res
2009; 29: 4019–4024.19846945
KrawczykN
BanysM
NeubauerH
, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res
2009; 29: 4019–4024.19846945,
KrawczykN
BanysM
NeubauerH
, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res
2009; 29: 4019–4024.19846945
-
(
NazhaB
InalC
OwonikokoTK
. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol
2020; 10: 1–15.32076595)
NazhaB
InalC
OwonikokoTK
. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol
2020; 10: 1–15.32076595
NazhaB
InalC
OwonikokoTK
. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol
2020; 10: 1–15.32076595,
NazhaB
InalC
OwonikokoTK
. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol
2020; 10: 1–15.32076595
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
Yi
Liu,
Qian
Liu,
Tao
Wang,
L.
Bian,
Shaohua
Zhang,
Hai-xu
Hu,
Sha
Li,
Zhiyuan
Hu,
Shikai
Wu,
Bing
Liu,
Zefei
Jiang
(2013)
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
BMC Cancer, 13
-
(
CoccoS
PiezzoM
CalabreseA
, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci
2020; 21: 1–34.)
CoccoS
PiezzoM
CalabreseA
, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci
2020; 21: 1–34.
CoccoS
PiezzoM
CalabreseA
, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci
2020; 21: 1–34.,
CoccoS
PiezzoM
CalabreseA
, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci
2020; 21: 1–34.
-
M.
Mansoori,
R.
Roudi,
A.
Abbasi,
M.
Abolhasani,
Isa
Rad,
A.
Shariftabrizi,
Z.
Madjd
(2019)
High GD2 expression defines breast cancer cells with enhanced invasiveness.
Experimental and molecular pathology, 109
-
T.
Fehm,
N.
Krawczyk,
E.
Solomayer,
G.
Becker‐Pergola,
S.
Dürr-Störzer,
H.
Neubauer,
H.
Seeger,
A.
Staebler,
D.
Wallwiener,
S.
Becker
(2008)
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
Breast Cancer Research : BCR, 10
-
(
Van der HageJA
van de VeldeCJ
JulienJP
, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol
2001; 19: 4224–4237.11709566)
Van der HageJA
van de VeldeCJ
JulienJP
, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol
2001; 19: 4224–4237.11709566
Van der HageJA
van de VeldeCJ
JulienJP
, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol
2001; 19: 4224–4237.11709566,
Van der HageJA
van de VeldeCJ
JulienJP
, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol
2001; 19: 4224–4237.11709566
-
(2017)
Abstract P 1 - 0101 : Circulating tumor cell number and CTC - endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients : Results of the COMETI Phase 2 trial
-
W.
Sikov,
D.
Berry,
C.
Perou,
Baljit
Singh,
C.
Cirrincione,
S.
Tolaney,
C.
Kuzma,
T.
Pluard,
G.
Somlo,
E.
Port,
M.
Golshan,
J.
Bellon,
D.
Collyar,
O.
Hahn,
L.
Carey,
C.
Hudis,
E.
Winer
(2015)
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 1
-
(
ColleoniM
BonettiM
CoatesAS
, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: the International Breast Cancer Study Group. J Clin Oncol
2000; 18: 584–590.10653873)
ColleoniM
BonettiM
CoatesAS
, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: the International Breast Cancer Study Group. J Clin Oncol
2000; 18: 584–590.10653873
ColleoniM
BonettiM
CoatesAS
, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: the International Breast Cancer Study Group. J Clin Oncol
2000; 18: 584–590.10653873,
ColleoniM
BonettiM
CoatesAS
, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: the International Breast Cancer Study Group. J Clin Oncol
2000; 18: 584–590.10653873
-
(
YusaA
ToneriM
MasudaT
, et al. Development of a new rapid isolation device for circulating tumor cells (CTCs) using palladium filter and its application for genetic analysis. PLoS One
2014; 9: e88821.24523941)
YusaA
ToneriM
MasudaT
, et al. Development of a new rapid isolation device for circulating tumor cells (CTCs) using palladium filter and its application for genetic analysis. PLoS One
2014; 9: e88821.24523941
YusaA
ToneriM
MasudaT
, et al. Development of a new rapid isolation device for circulating tumor cells (CTCs) using palladium filter and its application for genetic analysis. PLoS One
2014; 9: e88821.24523941,
YusaA
ToneriM
MasudaT
, et al. Development of a new rapid isolation device for circulating tumor cells (CTCs) using palladium filter and its application for genetic analysis. PLoS One
2014; 9: e88821.24523941
-
Akiko
Yusa,
Makoto
Toneri,
T.
Masuda,
S.
Ito,
Shûhei
Yamamoto,
M.
Okochi,
N.
Kondo,
H.
Iwata,
Y.
Yatabe,
Yoshiyuki
Ichinosawa,
S.
Kinuta,
E.
Kondo,
H.
Honda,
F.
Arai,
H.
Nakanishi
(2014)
Development of a New Rapid Isolation Device for Circulating Tumor Cells (CTCs) Using 3D Palladium Filter and Its Application for Genetic Analysis
PLoS ONE, 9
-
D.
Yardley,
R.
Weaver,
M.
Melisko,
M.
Saleh,
F.
Arena,
A.
Forero,
T.
Cigler,
A.
Stopeck,
D.
Citrin,
I.
Oliff,
R.
Bechhold,
R.
Loutfi,
Agustin
Garcia,
S.
Cruickshank,
E.
Crowley,
Jennifer
Green,
T.
Hawthorne,
M.
Yellin,
T.
Davis,
L.
Vahdat
(2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 14
-
P.
Rastogi,
S.
Anderson,
H.
Bear,
C.
Geyer,
M.
Kahlenberg,
A.
Robidoux,
R.
Margolese,
J.
Hoehn,
V.
Vogel,
S.
Dakhil,
D.
Tamkus,
K.
King,
E.
Pajon,
Mary
Wright,
J.
Robert,
S.
Paik,
E.
Mamounas,
N.
Wolmark
(2008)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
-
(
PiergaJY
BidardFC
AutretA
, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol
2017; 28: 103–109.28177480)
PiergaJY
BidardFC
AutretA
, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol
2017; 28: 103–109.28177480
PiergaJY
BidardFC
AutretA
, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol
2017; 28: 103–109.28177480,
PiergaJY
BidardFC
AutretA
, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol
2017; 28: 103–109.28177480
-
T.
Fehm,
V.
Müller,
B.
Aktas,
W.
Janni,
A.
Schneeweiss,
E.
Stickeler,
C.
Lattrich,
Christian
Löhberg,
E.
Solomayer,
B.
Rack,
S.
Riethdorf,
C.
Klein,
C.
Schindlbeck,
K.
Brocker,
S.
Kasimir-Bauer,
D.
Wallwiener,
K.
Pantel
(2010)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Breast Cancer Research and Treatment, 124
-
(2010)
Use of CTCs in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: the SUCCESS trial